1 |
Kaito H, Kamei K, Kikuchi E, Ogura M, Matsuoka K, Nagata M, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of RTX, steroids and ciclosporin. Pediatr Nephrol 2010;25:957-9.
DOI
|
2 |
Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. RTX in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012;23:1117-24.
DOI
|
3 |
Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating RTX to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7.
DOI
|
4 |
Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of RTX for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321-8.
DOI
|
5 |
Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, et al. Single infusion of RTX for persistent steroid-dependent minimalchange nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010;25:539-44.
DOI
|
6 |
Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, et al. Survey of RTX treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2013;28:257-64.
DOI
|
7 |
Niu X-L, Hao S, Wang P, Zhang W, Guo G-M, Wu Y, et al. Single dose of RTX in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep 2016;5:237-42.
DOI
|
8 |
Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 2013;28:911-8.
DOI
|
9 |
Cornec D, Tempescul A, Querellou S, Hutin P, Pers J-O, Jamin C, et al. Identification of patients with indolent B cell lymphoma sensitive to RTX monotherapy. Ann Hematol 2012;91:715-21.
DOI
|
10 |
Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with RTX: a Japanese phase II study. Ann Oncol 2002;13:928-43.
DOI
|
11 |
Ahn YH, Kang HG, Lee JM, Choi HJ, Ha I-S, Cheong HI. Development of antiRTX antibodies in children with nephrotic syndrome. Pediatr Nephrol 2014;29:1461-4.
DOI
|
12 |
Chaumais M-C, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, et al.Fatal pulmonary fibrosis after RTX administration. Pediatr Nephrol 2009;24:1753-5.
DOI
|
13 |
Sellier-Leclerc A-L, Belli E, Guerin V, Dorfmuller P, Deschenes G. Fulminant viral myocarditis after RTX therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013;28:1875-9.
DOI
|
14 |
Ehrich JHH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22:2183-93.
DOI
|
15 |
Kyrieleis HAC, Lowik MM, Pronk I, Cruysberg HRM, Kremer JAM, Oyen WJG, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol CJASN 2009;4:1593-600.
DOI
|
16 |
Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. RTX treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008;23:1269-79.
DOI
|
17 |
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of RTX. Arthritis Rheum 2004;50:2580-9.
DOI
|
18 |
Bagga A, Sinha A, Moudgil A. RTX in patients with the steroidresistant nephrotic syndrome. N Engl J Med 2007;356:2751-2.
DOI
|
19 |
Gilbert RD, Hulse E, Rigden S. RTX therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006;21: 1698-700.
DOI
|
20 |
Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of RTX in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
DOI
|
21 |
Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after RTX therapy. Pediatr Nephrol 2004;19:794-7.
DOI
|
22 |
Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, et al. Efficacy and safety of RTX in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 2015;30:96-106.
DOI
|
23 |
Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after RTX for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012;27:1910-5.
DOI
|
24 |
Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. RTX for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384:1273-81.
DOI
|
25 |
Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with RTX for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010;5:2207-12.
DOI
|